Physiological and Pharmacological Actions of Glucagon Like Peptide-1 (GLP-1) in Domestic Animals

Overview

Journal Vet Anim Sci

Specialty Veterinary Medicine

Date 2022 Apr 4

PMID 35372707

Authors

Jorge F A Model

Debora S Rocha

Alessa da C Fagundes

Anapaula S Vinagre

Affiliations

Soon will be listed here.

Abstract

Analogues of glucagon like peptide-1 (GLP-1) and other drugs that increase this peptide half-life are used worldwide in human medicine to treat type 2 diabetes mellitus (DM) and obesity. These molecules can increase insulin release and satiety, interesting effects that could also be useful in the treatment of domestic animals pathologies, however their use in veterinary medicine are still limited. Considering the increasing incidence of DM and obesity in cats and dogs, the aim of this review is to summarize the available information about the physiological and pharmacological actions of GLP-1 in domestic animals and discuss about its potential applications in veterinary medicine. In diabetic dogs, the use of drugs based on GLP-1 actions reduced blood glucose and increased glucose uptake, while in diabetic cats they reduced glycemic variability and exogenous insulin administration. Thus, available evidence indicates that GLP-1 based drugs could become alternatives to DM treatment in domestic animals. Nevertheless, current data do not provide enough elements to recommend these drugs widespread clinical use.

Citing Articles

Replacement of Dietary Carbohydrate with Protein versus Fat Differentially Alters Postprandial Circulating Hormones and Macronutrient Metabolism in Dogs.

Jackson M Metabolites. 2024; 14(7).

PMID: 39057696 PMC: 11279194. DOI: 10.3390/metabo14070373.

Examining the Potential Applicability of Orexigenic and Anorexigenic Peptides in Veterinary Medicine for the Management of Obesity in Companion Animals.

Osiak-Wicha C, Kras K, Tomaszewska E, Muszynski S, Arciszewski M Curr Issues Mol Biol. 2024; 46(7):6725-6745.

PMID: 39057043 PMC: 11275339. DOI: 10.3390/cimb46070401.

Advances in Drug Treatments for Companion Animal Obesity.

Zomer H, Cooke P Biology (Basel). 2024; 13(5).

PMID: 38785817 PMC: 11117622. DOI: 10.3390/biology13050335.

Short-term changes in dietary fat levels and starch sources affect weight management, glucose and lipid metabolism, and gut microbiota in adult cats.

Mo R, Zhang M, Wang H, Liu T, Zhang G, Wu Y J Anim Sci. 2023; 101.

PMID: 37602405 PMC: 10465269. DOI: 10.1093/jas/skad276.

Characterization of the Gut Microbiome in Healthy Dogs and Dogs with Diabetes Mellitus.

Kwong T, Chau E, Mak M, Choy C, Chan L, Pang C Animals (Basel). 2023; 13(15).

PMID: 37570288 PMC: 10417117. DOI: 10.3390/ani13152479.

References

Padrutt I, Lutz T, Reusch C, Zini E . Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats. Res Vet Sci. 2015; 99:23-9. DOI: 10.1016/j.rvsc.2014.12.001. View

Drucker D . The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications. Diabetes. 2018; 67(9):1710-1719. DOI: 10.2337/dbi18-0008. View

MacDonald P, Wang X, Xia F, El-Kholy W, Targonsky E, Tsushima R . Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. J Biol Chem. 2003; 278(52):52446-53. DOI: 10.1074/jbc.M307612200. View

Furrer D, Kaufmann K, Tschuor F, Reusch C, Lutz T . The dipeptidyl peptidase IV inhibitor NVP-DPP728 reduces plasma glucagon concentration in cats. Vet J. 2009; 183(3):355-7. DOI: 10.1016/j.tvjl.2008.11.017. View

McMillan C, Zapata R, Chelikani P, Snead E, Cosford K . Circulating concentrations of glucagon-like peptide 1, glucose-dependent insulinotropic peptide, peptide YY, and insulin in client-owned lean, overweight, and diabetic cats. Domest Anim Endocrinol. 2015; 54:85-94. DOI: 10.1016/j.domaniend.2015.10.001. View

Sirohi S, Schurdak J, Seeley R, Benoit S, Davis J . Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors. Physiol Behav. 2016; 161:140-144. DOI: 10.1016/j.physbeh.2016.04.013. View

Dardevet D, Moore M, DiCostanzo C, Farmer B, Neal D, Snead W . Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am J Physiol Gastrointest Liver Physiol. 2005; 289(5):G806-14. PMC: 2435373. DOI: 10.1152/ajpgi.00121.2005. View

Ruttimann E, Arnold M, Hillebrand J, Geary N, Langhans W . Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology. 2008; 150(3):1174-81. PMC: 2654737. DOI: 10.1210/en.2008-1221. View

Maske C, Jackson C, Terrill S, Eckel L, Williams D . Estradiol modulates the anorexic response to central glucagon-like peptide 1. Horm Behav. 2017; 93:109-117. PMC: 5555302. DOI: 10.1016/j.yhbeh.2017.05.012. View

10.

Riederer A, Zini E, Salesov E, Fracassi F, Padrutt I, Macha K . Effect of the Glucagon-like Peptide-1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus. J Vet Intern Med. 2015; 30(1):92-100. PMC: 4913624. DOI: 10.1111/jvim.13817. View

11.

Shimoda M, Kanda Y, Hamamoto S, Tawaramoto K, Hashiramoto M, Matsuki M . The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia. 2011; 54(5):1098-108. PMC: 3071950. DOI: 10.1007/s00125-011-2069-9. View

12.

Bunemann M, Gerhardstein B, Gao T, Hosey M . Functional regulation of L-type calcium channels via protein kinase A-mediated phosphorylation of the beta(2) subunit. J Biol Chem. 1999; 274(48):33851-4. DOI: 10.1074/jbc.274.48.33851. View

13.

Rowlands J, Heng J, Newsholme P, Carlessi R . Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Front Endocrinol (Lausanne). 2018; 9:672. PMC: 6266510. DOI: 10.3389/fendo.2018.00672. View

14.

Mori A, Ueda K, Lee P, Oda H, Ishioka K, Arai T . Effect of Acarbose, Sitagliptin and combination therapy on blood glucose, insulin, and incretin hormone concentrations in experimentally induced postprandial hyperglycemia of healthy cats. Res Vet Sci. 2016; 106:131-4. DOI: 10.1016/j.rvsc.2016.04.001. View

15.

Wang Y, Egan J, Raygada M, Nadiv O, Roth J, Montrose-Rafizadeh C . Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology. 1995; 136(11):4910-7. DOI: 10.1210/endo.136.11.7588224. View

16.

Rudinsky A, Adin C, Borin-Crivellenti S, Rajala-Schultz P, Hall M, Gilor C . Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats. Domest Anim Endocrinol. 2015; 51:78-85. DOI: 10.1016/j.domaniend.2014.12.003. View

17.

Edgerton D, Johnson K, Neal D, Scott M, Hobbs C, Zhang X . Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog. Diabetes. 2008; 58(1):243-9. PMC: 2606880. DOI: 10.2337/db08-0515. View

18.

Hoenig M, Pach N, Thomaseth K, Le A, Schaeffer D, Ferguson D . Cats differ from other species in their cytokine and antioxidant enzyme response when developing obesity. Obesity (Silver Spring). 2013; 21(9):E407-14. DOI: 10.1002/oby.20306. View

19.

Abd El Aziz M, Cahyadi O, Meier J, Schmidt W, Nauck M . Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab. 2019; 22(4):699-704. DOI: 10.1111/dom.13924. View

20.

Ohnuma K, Dang N, Morimoto C . Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function. Trends Immunol. 2008; 29(6):295-301. DOI: 10.1016/j.it.2008.02.010. View